Ogivri Approval History

FDA Approved: Yes (First approved December 1, 2017)
Brand name: Ogivri
Generic name: trastuzumab-dkst
Dosage form: for Injection
Company: Mylan GmbH
Treatment for: Breast Cancer, Gastric Cancer

Ogivri (trastuzumab-dkst) is a HER2/neu receptor antagonist biosimilar to Herceptin indicated for the treatment of HER2-overexpressing breast cancer and the treatment of HER2-overexpressing stomach cancer.

Development History and FDA Approval Process for Ogivri

Date	Article
Dec  1, 2017	FDA Approves Ogivri (trastuzumab-dkst), a Biosimilar to Herceptin
Jan 11, 2017	U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer